Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 3.75
ACRX's Cash to Debt is ranked higher than
79% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. ACRX: 3.75 )
ACRX' s 10-Year Cash to Debt Range
Min: 0.31   Max: No Debt
Current: 3.75

Equity to Asset 0.55
ACRX's Equity to Asset is ranked higher than
64% of the 757 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. ACRX: 0.55 )
ACRX' s 10-Year Equity to Asset Range
Min: -0.01   Max: 0.69
Current: 0.55

-0.01
0.69
F-Score: 4
Z-Score: 2.53
M-Score: 4.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -32.23
ACRX's Operating margin (%) is ranked higher than
52% of the 787 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.15 vs. ACRX: -32.23 )
ACRX' s 10-Year Operating margin (%) Range
Min: -1805.22   Max: -22.6
Current: -32.23

-1805.22
-22.6
Net-margin (%) -47.40
ACRX's Net-margin (%) is ranked higher than
52% of the 787 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.39 vs. ACRX: -47.40 )
ACRX' s 10-Year Net-margin (%) Range
Min: -1875.09   Max: -79.4
Current: -47.4

-1875.09
-79.4
ROE (%) -26.53
ACRX's ROE (%) is ranked higher than
52% of the 796 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.47 vs. ACRX: -26.53 )
ACRX' s 10-Year ROE (%) Range
Min: -130.03   Max: -43.78
Current: -26.53

-130.03
-43.78
ROA (%) -15.53
ACRX's ROA (%) is ranked higher than
53% of the 815 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. ACRX: -15.53 )
ACRX' s 10-Year ROA (%) Range
Min: -134.55   Max: -26.84
Current: -15.53

-134.55
-26.84
ROC (Joel Greenblatt) (%) -190.80
ACRX's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.76 vs. ACRX: -190.80 )
ACRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2973.59   Max: -173.98
Current: -190.8

-2973.59
-173.98
EBITDA Growth (%) -68.80
ACRX's EBITDA Growth (%) is ranked lower than
53% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. ACRX: -68.80 )
ACRX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -65
Current: -68.8

EPS Growth (%) -70.00
ACRX's EPS Growth (%) is ranked higher than
50% of the 627 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. ACRX: -70.00 )
ACRX' s 10-Year EPS Growth (%) Range
Min: 0   Max: -64.9
Current: -70

» ACRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

ACRX Guru Trades in Q4 2012

Louis Moore Bacon 150,000 sh (New)
» More
Q1 2013

ACRX Guru Trades in Q1 2013

Louis Moore Bacon Sold Out
» More
Q1 2014

ACRX Guru Trades in Q1 2014

Louis Moore Bacon 36,000 sh (New)
» More
Q2 2014

ACRX Guru Trades in Q2 2014

Louis Moore Bacon 50,000 sh (+38.89%)
» More
» Details

Insider Trades

Latest Guru Trades with ACRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.30
ACRX's P/B is ranked higher than
52% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.31 vs. ACRX: 5.30 )
ACRX' s 10-Year P/B Range
Min: 2.16   Max: 78
Current: 5.3

2.16
78
EV-to-EBIT -25.04
ACRX's EV-to-EBIT is ranked higher than
50% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.86 vs. ACRX: -25.04 )
ACRX' s 10-Year EV-to-EBIT Range
Min: -68.6   Max: -1.1
Current: -25.04

-68.6
-1.1
Current Ratio 10.67
ACRX's Current Ratio is ranked higher than
96% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. ACRX: 10.67 )
ACRX' s 10-Year Current Ratio Range
Min: 0.43   Max: 20.39
Current: 10.67

0.43
20.39
Quick Ratio 10.67
ACRX's Quick Ratio is ranked higher than
96% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. ACRX: 10.67 )
ACRX' s 10-Year Quick Ratio Range
Min: 0.43   Max: 20.39
Current: 10.67

0.43
20.39

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.16
ACRX's Price/Net Cash is ranked higher than
96% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ACRX: 6.16 )
ACRX' s 10-Year Price/Net Cash Range
Min: 2.2   Max: 25
Current: 6.16

2.2
25
Price/Net Current Asset Value 6.16
ACRX's Price/Net Current Asset Value is ranked higher than
92% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ACRX: 6.16 )
ACRX' s 10-Year Price/Net Current Asset Value Range
Min: 2.2   Max: 25
Current: 6.16

2.2
25
Price/Tangible Book 5.30
ACRX's Price/Tangible Book is ranked higher than
69% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.93 vs. ACRX: 5.30 )
ACRX' s 10-Year Price/Tangible Book Range
Min: 2.08   Max: 57.94
Current: 5.3

2.08
57.94
Earnings Yield (Greenblatt) -4.00
ACRX's Earnings Yield (Greenblatt) is ranked lower than
87% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. ACRX: -4.00 )
ACRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:R5X.Germany
Acelrx Pharmaceuticals Inc. is a specialty pharmaceutical company involved in the development and commercialization of therapies for the treatment of acute and breakthrough pain.
» More Articles for ACRX

Headlines

Articles On GuruFocus.com
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against AcelRx Pharmaceutica Oct 15 2014 
Weekly CFO Buys Highlight: BK, MWW, BLD, ACRX, PSEC Sep 12 2011 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Oct 23 2014
EQUITY ALERT: Rosen Law Firm P.A. Reminds AcelRx Pharmaceuticals, Inc. Investors of Important Class... Oct 22 2014
AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results Oct 22 2014
AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results Oct 22 2014
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against AcelRx... Oct 20 2014
AcelRx Pharmaceuticals Provides Update on its Patent Portfolio for Zalviso™ and its Proprietary... Oct 16 2014
AcelRx Pharmaceuticals Provides Update on its Patent Portfolio for Zalviso™ and its Proprietary... Oct 16 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Oct 15 2014
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against AcelRx... Oct 10 2014
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $50,000... Oct 10 2014
AcelRx Pharmaceuticals Announces Multiple Sublingual Sufentanil Data Presentations At The American... Oct 10 2014
Robbins Arroyo LLP: AcelRx Pharmaceuticals, Inc. (ACRX) Misled Shareholders According to a Recently... Oct 08 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Oct 07 2014
Harwood Feffer LLP Announces Investigation of AcelRx Pharmaceuticals, Inc. Oct 07 2014
Lifshitz & Miller Law Firm Announces Investigation of AcelRx Pharmaceuticals, Inc., Ambit... Oct 07 2014
AcelRx Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor... Oct 07 2014
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against AcelRx... Oct 06 2014
EQUITY ALERT: The Rosen Law Firm P.A. Announced Filing of Securities Class Action Against AcelRx... Oct 06 2014
UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against AcelRx... Oct 06 2014
Sufentanil sublingual tablet system study results to be presented at the International Association... Oct 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK